Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study (Q61054098)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

title

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

F Oliveri

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Gioacchino Leandro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Piero Colombatto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Ferruccio Bonino

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

Barbara Coco

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Juliana Monti Gorin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 February 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

263-270

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver.

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Detection and characterization of hepatitis B virus DNA in serum of HBe antigen-negative HBsAg carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Natural history and prognostic factors for chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

The long-term course of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Hepatocellular carcinoma in Italian patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Hepatitis B therapy: the plot thickens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900266-5

7 January 2021

10.1016/S0168-8278(01)00266-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830339%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference